ArticleESMO open2026

Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM).

H Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.